PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6538212

[Androgen binding components in the human placenta].

H Kanasugi
View original source ↗Export metadata ↓

Abstract

In the present study, characterization of the androgen binding components in human term placenta was undertaken. Scatchard analysis revealed the presence of high affinity binding components with dissociation constants (Kd) of 1.5 X 10(-10)M and 3.7 X 10(-9)M for dihydrotestosterone (DHT) in hormone-striped placental cytosol. Isoelectric focusing (IEF) after equilibration with 20 nM 3H-DHT indicated three binding activities with elution pH (Pe) of 4.6, 5.3 and 6.0. The placental cytosol was then fractionated into Concanavalin-A Sepharose (Con-A). The Con-A unbound fraction contained two heat labile binding populations for DHT with Kd's of 1.9 +/- 0.4 X 10(-10)M and 5.9 +/- 1.2 X 10(-9)M (mean +/- SE: n = 6), and two peaks on IEF with 20nM 3H-DHT with Pe's of 4.6 and 6.0. When IEF was performed with 2 nM 3H-DHT, only one peak was observed with a Pe of 6.0. The Con-A bound fraction contained a heat stable, single binding population for DHT with a Kd of 2.2 +/- 0.2 X 10(-10)M and a Pe of 5.0. It appears that the binding population is testosterone-estradiol binding globulin (TeBG). In competitive binding studies, androstenedione, dehydroepiandrosterone and dehydroepiandrosterone-sulfate had much higher affinities for Con-A unbound fraction than Con-A bound fraction. Therefore, it appears that there are at least two androgen binding components in human term placental cytosol, demonstrable after removal of TeBG contamination, that can be shown to have different affinities for DHT and, probably, separate Pe's.

Explore related subjects

Androgen-Binding ProteinBinding, CompetitiveCarrier ProteinsConcanavalin ACytosolDihydrotestosteroneFemaleHumansIsoelectric FocusingPlacentaPregnancyReceptors, AndrogenSex Hormone-Binding GlobulinEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Kanasugi. 1984. [Androgen binding components in the human placenta].. https://pubmed.ncbi.nlm.nih.gov/6538212/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Variant in sex hormone-binding globulin gene and the risk of prostate cancer.

Sex hormones have been implicated in prostate carcinogenesis and are thought to modulate cell proliferation and growth. To investigate the association between polymorphisms in hormone-related genes and prostate cancer risk, we conducted a two-stage, case-control study within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Using DNA extracted from blood specimens, we initially genotyped 14 single nucleotide polymorphisms in genes involved in hormone regulation or metabolism (AKR1C3, CYP1A1, CYP1B1, CYP3A4, ESR1, GNRH1, HSD173B, HSD3B2, SHBG, and SRD5A2) in 488 prostate cancer cases and 617 matched controls. Heterozygotes at SHBG D356N were found to be associated with an increased risk of prostate cancer compared with the homozygous wild type, particularly among non-Hispanic whites (odds ratio, 1.54; 95% confidence interval, 1.13-2.09; P = 0.006). No significant associations were observed with the other polymorphisms. The SHBG D356N polymorphism, which has potential functional significance, was subsequently genotyped in additional 769 cases and 1,168 controls. Overall, SHBG D356N heterozygotes were found to have an increased risk of prostate cancer among whites (odds ratio, 1.34; 95% confidence interval, 1.10-1.63; P = 0.0007). This study suggests that genetic variation in SHBG may influence prostate cancer susceptibility.

Androgen-Binding Protein↗
PubMed2006

Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice.

Although antiandrogen therapy has been shown effective in treating prostatic tumors, it is relatively ineffective in treating benign prostatic hyperplasia (BPH). In an attempt to understand better the role of androgens in the development of the normal prostate and BPH, we studied the relative effects of testosterone and IGF-I on the development of the two compartments of the prostate in castrated IGF-I((-/-)) male mice. Here we report that IGF-I stimulated the development of the fibromuscular compartment, but testosterone inhibited it (stromal epithelial ratio 2.17 vs. 0.83, respectively; P < 0.001). Testosterone also impaired IGF-I induced insulin receptor substrate-1 phosphorylation and cell division, and increased apoptosis in fibromuscular tissue. In sharp contrast IGF-I and testosterone both stimulated the development of the glandular compartment individually and together. The combined effects were either additive or synergistic on compartment size, cell division, insulin receptor substrate-1 phosphorylation, and probasin production. Together they also had a greater inhibitory effect on apoptosis in gland tissue. To determine whether IGF-I inhibition would inhibit both fibromuscular and glandular compartments, we tested the effect of IGF binding protein-1 on prostate development in two different models: castrated Ames dwarf mice and eugonadal normal male mice. IGF binding protein-1 blocked bovine GH-induced fibromuscular and glandular development in both. It also inhibited epithelial cell division and increased apoptosis in both prostate compartments in the eugonadal mice. The observed discordance between IGF-I and testosterone control of prostate compartment development might explain the relative failure of 5alpha-reductase inhibition in BPH and why testosterone inhibition might theoretically reduce gland volume but increase fibromuscular tissue. The work also provides a rationale for considering IGF-I inhibition as therapy for BPH to reduce the size of both prostate compartments.

Androgen-Binding Protein↗
PubMed2006

Identification of putative androgen receptor interaction protein modules: cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells.

We have developed a novel androgen receptor (AR) expression system in the 293 human embryonic kidney cell line that recapitulates AR biochemical activity as a steroid hormone receptor in prostate cancer cells. We used this system to identify putative AR-binding proteins in the cytosolic and nuclear compartments of mammalian cells using a large scale co-immunoprecipitation strategy coupled to quantitative mass spectrometry. For example, the heat shock 70 and 90 chaperones, which are known regulators of steroid hormone receptor, were identified as AR-binding proteins. AR purification enriched for proteins involved in RNA processing, protein transport, and cytoskeletal organization, suggesting a functional link between AR and these protein modules in mammalian cells. For example, AR purification in the nuclear compartment led to the specific enrichment of alpha-actinin-4, clathrin heavy chain, and serine-threonine protein kinase C delta. Short interfering RNA knockdown studies and co-transcriptional reporter assays revealed that clathrin heavy chain possessed co-activator activity during AR-mediated transcription, whereas alpha-actinin-4 and protein kinase C delta displayed both co-activator and co-repressor activity during AR-mediated transcription that was dependent upon their relative expression levels. Lastly immunohistochemical staining of prostate tissue showed that alpha-actinin-4 levels decreased in the nucleus of high grade cancerous prostate samples, suggesting its possible deregulation in advanced prostate cancers as previously observed in late stage metastatic breast cancers. Taken together, these findings suggest AR binds to specific protein modules in mammalian cells and that these protein modules may provide a molecular framework for interrogating AR function in normal and cancerous prostate epithelial cells.

Androgen-Binding Protein↗